Literature DB >> 22172721

Oncogene-targeting T cells reject large tumors while oncogene inactivation selects escape variants in mouse models of cancer.

Kathleen Anders1, Christian Buschow, Andreas Herrmann, Ana Milojkovic, Christoph Loddenkemper, Thomas Kammertoens, Peter Daniel, Hua Yu, Jehad Charo, Thomas Blankenstein.   

Abstract

The genetic instability of cancer cells frequently causes drug resistance. We established mouse cancer models, which allowed targeting of an oncogene by drug-mediated inactivation or monospecific CD8(+) effector T (T(E)) cells. Drug treatment of genetically unstable large tumors was effective but selected resistant clones in the long term. In contrast, T(E) cells completely rejected large tumors (≥500 mm(3)), if the target antigen was cancer-driving and expressed in sufficient amounts. Although drug-mediated oncogene inactivation selectively killed the cancer cells and left the tumor vasculature intact, which likely facilitated survival and growth of resistant clones, T(E) cell treatment led to blood vessel destruction and probably "bystander" elimination of escape variants, which did not require antigen cross-presentation by stromal cells.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22172721      PMCID: PMC3658305          DOI: 10.1016/j.ccr.2011.10.019

Source DB:  PubMed          Journal:  Cancer Cell        ISSN: 1535-6108            Impact factor:   31.743


  45 in total

Review 1.  The role of autophagy in cancer development and response to therapy.

Authors:  Yasuko Kondo; Takao Kanzawa; Raymond Sawaya; Seiji Kondo
Journal:  Nat Rev Cancer       Date:  2005-09       Impact factor: 60.716

2.  Diversity of escape variant mutations in Simian virus 40 large tumor antigen (SV40 Tag) epitopes selected by cytotoxic T lymphocyte (CTL) clones.

Authors:  Lawrence M Mylin; Todd D Schell; Melanie Epler; Caroline Kusuma; David Assis; Chelsea Matsko; Alexandra Smith; April Allebach; Satvir S Tevethia
Journal:  Virology       Date:  2007-03-21       Impact factor: 3.616

Review 3.  Cancer immunotherapy and preclinical studies: why we are not wasting our time with animal experiments.

Authors:  Karin Schreiber; Donald A Rowley; Gert Riethmüller; Hans Schreiber
Journal:  Hematol Oncol Clin North Am       Date:  2006-06       Impact factor: 3.722

4.  In vivo assessment of RAS-dependent maintenance of tumor angiogenesis by real-time magnetic resonance imaging.

Authors:  Yi Tang; Minjung Kim; Daniel Carrasco; Andrew L Kung; Lynda Chin; Ralph Weissleder
Journal:  Cancer Res       Date:  2005-09-15       Impact factor: 12.701

5.  Solid tumors "melt" from the inside after successful CD8 T cell attack.

Authors:  Ulrike Blohm; Dan Potthoff; Albert J van der Kogel; Hanspeter Pircher
Journal:  Eur J Immunol       Date:  2006-02       Impact factor: 5.532

6.  Clonal integration of a polyomavirus in human Merkel cell carcinoma.

Authors:  Huichen Feng; Masahiro Shuda; Yuan Chang; Patrick S Moore
Journal:  Science       Date:  2008-01-17       Impact factor: 47.728

Review 7.  Overcoming immune evasion in T cell therapy of cancer: lessons from animal models.

Authors:  Jin-Qing Liu; Xue-Feng Bai
Journal:  Curr Mol Med       Date:  2008-02       Impact factor: 2.222

8.  LC3-mediated fibronectin mRNA translation induces fibrosarcoma growth by increasing connective tissue growth factor.

Authors:  Lihua Ying; Agatha Lau; Cristina M Alvira; Robert West; Gordon M Cann; Bin Zhou; Caroline Kinnear; Eric Jan; Peter Sarnow; Matt Van de Rijn; Marlene Rabinovitch
Journal:  J Cell Sci       Date:  2009-04-14       Impact factor: 5.285

9.  IFN-gamma- and TNF-dependent bystander eradication of antigen-loss variants in established mouse cancers.

Authors:  Bin Zhang; Theodore Karrison; Donald A Rowley; Hans Schreiber
Journal:  J Clin Invest       Date:  2008-04       Impact factor: 14.808

10.  Immunogenicity of premalignant lesions is the primary cause of general cytotoxic T lymphocyte unresponsiveness.

Authors:  Gerald Willimsky; Melinda Czéh; Christoph Loddenkemper; Johanna Gellermann; Karin Schmidt; Peter Wust; Harald Stein; Thomas Blankenstein
Journal:  J Exp Med       Date:  2008-06-23       Impact factor: 14.307

View more
  23 in total

1.  Depot formation of doxycycline impairs Tet-regulated gene expression in vivo.

Authors:  Kathleen Anders; Christian Buschow; Jehad Charo; Thomas Blankenstein
Journal:  Transgenic Res       Date:  2011-12-14       Impact factor: 2.788

2.  Effective NY-ESO-1-specific MHC II-restricted T cell receptors from antigen-negative hosts enhance tumor regression.

Authors:  Lucia Poncette; Xiaojing Chen; Felix Km Lorenz; Thomas Blankenstein
Journal:  J Clin Invest       Date:  2018-12-10       Impact factor: 14.808

3.  Tumour ischaemia by interferon-γ resembles physiological blood vessel regression.

Authors:  Thomas Kammertoens; Christian Friese; Ainhoa Arina; Christian Idel; Dana Briesemeister; Michael Rothe; Andranik Ivanov; Anna Szymborska; Giannino Patone; Severine Kunz; Daniel Sommermeyer; Boris Engels; Matthias Leisegang; Ana Textor; Hans Joerg Fehling; Marcus Fruttiger; Michael Lohoff; Andreas Herrmann; Hua Yu; Ralph Weichselbaum; Wolfgang Uckert; Norbert Hübner; Holger Gerhardt; Dieter Beule; Hans Schreiber; Thomas Blankenstein
Journal:  Nature       Date:  2017-04-26       Impact factor: 49.962

Review 4.  An essential role for the immune system in the mechanism of tumor regression following targeted oncogene inactivation.

Authors:  Stephanie C Casey; Yulin Li; Dean W Felsher
Journal:  Immunol Res       Date:  2014-05       Impact factor: 2.829

Review 5.  Adoptive immunotherapy for cancer: harnessing the T cell response.

Authors:  Nicholas P Restifo; Mark E Dudley; Steven A Rosenberg
Journal:  Nat Rev Immunol       Date:  2012-03-22       Impact factor: 53.106

6.  CD8+ T-cell responses rapidly select for antigen-negative tumor cells in the prostate.

Authors:  S Peter Bak; Mike Stein Barnkob; K Dane Wittrup; Jianzhu Chen
Journal:  Cancer Immunol Res       Date:  2013-09-20       Impact factor: 11.151

7.  Virus-induced hepatocellular carcinomas cause antigen-specific local tolerance.

Authors:  Gerald Willimsky; Karin Schmidt; Christoph Loddenkemper; Johanna Gellermann; Thomas Blankenstein
Journal:  J Clin Invest       Date:  2013-02-01       Impact factor: 14.808

8.  Relapse or eradication of cancer is predicted by peptide-major histocompatibility complex affinity.

Authors:  Boris Engels; Victor H Engelhard; John Sidney; Alessandro Sette; David C Binder; Rebecca B Liu; David M Kranz; Stephen C Meredith; Donald A Rowley; Hans Schreiber
Journal:  Cancer Cell       Date:  2013-04-15       Impact factor: 31.743

9.  Fas expression by tumor stroma is required for cancer eradication.

Authors:  Joanna J Listopad; Thomas Kammertoens; Kathleen Anders; Bjoern Silkenstedt; Gerald Willimsky; Karin Schmidt; Anja A Kuehl; Christoph Loddenkemper; Thomas Blankenstein
Journal:  Proc Natl Acad Sci U S A       Date:  2013-01-22       Impact factor: 11.205

10.  Bladder cancer-associated cancer-testis antigen-derived long peptides encompassing both CTL and promiscuous HLA class II-restricted Th cell epitopes induced CD4+ T cells expressing converged T-cell receptor genes in vitro.

Authors:  Miki Tsuruta; Shohei Ueda; Poh Yin Yew; Isao Fukuda; Sachiko Yoshimura; Hiroyuki Kishi; Hiroshi Hamana; Masatoshi Hirayama; Junji Yatsuda; Atsushi Irie; Satoru Senju; Eiji Yuba; Tomomi Kamba; Masatoshi Eto; Hideki Nakayama; Yasuharu Nishimura
Journal:  Oncoimmunology       Date:  2018-01-05       Impact factor: 8.110

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.